Communicating safety information to physicians: an examination of dear doctor letters

被引:23
作者
Mazor, KM
Andrade, SE
Auger, J
Fish, L
Gurwitz, JH
机构
[1] Meyers Primary Care Inst, Worcester, MA 01605 USA
[2] Univ Massachusetts, Sch Med, Amherst, MA 01003 USA
[3] Fallon Fdn, Worcester, MA USA
[4] Fallon Community Hlth Plan, Worcester, MA USA
关键词
labeling; safety information; drug label change; dear doctor letters;
D O I
10.1002/pds.1102
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose Recent research suggests that letters to healthcare providers may not effectively communicate safety-related information. This study examined whether content, organization, and formatting of dear doctor letters (DDLs) influences physicians' responses to the letters. Methods Drugs with warning label changes during 2000 and 2001 were identified, and corresponding DDLs were obtained. Letters were coded for content, organization, and formatting. Ten physicians rated letters on presentation, criticalness of the information, and likelihood of changing practice as a result of the letter. Areas of deficiency were identified. The relationships between key characteristics of the letters and physicians' ratings were examined using correlations; reliability of physicians' ratings was estimated using generalizability theory. Results For 2000 and 2001, 124 drugs were identified as having had changes to the warning section of the label; DDLs were sent in 32 (25.8%) instances. Letters varied in terms of the placement of key information, use of formatting, and length. Physicians' ratings suggested 25% of the letters were deficient in clarity, 28% in readability, 36% in the ratio of relevant information to supporting information, 36% in key information easily discernable, and 28% in overall effectiveness of communication. Letters with formatting highlighting key information were preferred. Letter length and placement of key information were not correlated with physicians' ratings. Conclusions Many DDLs do not communicate labeling changes clearly and effectively. If DDLs are used to communicate safety information to physicians, special formatting and explicit wording should be used to emphasize new information. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:869 / 875
页数:7
相关论文
共 20 条
  • [1] BRENNAN RL, 2001, GENERALIZABILITY
  • [2] Conzola V.C., 2001, Journal of Risk Research, V4, P309, DOI [https://doi.org/10.1080/13669870110062712, 10.1080/13669870110062712, DOI 10.1080/13669870110062712, 10.1080/1366987011006271]
  • [3] Fry E.B., 1988, READABILITY ITS PRES, P77
  • [4] Liver enzyme monitoring in patients treated with troglitazone
    Graham, DJ
    Drinkard, CR
    Shatin, D
    Tsong, Y
    Burgess, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (07): : 831 - 833
  • [5] Gunning R., 1952, TECHNIQUE CLEAR WRIT
  • [6] Impact of cisapride label changes on codispensing of contraindicated medications
    Guo, JJ
    Curkendall, S
    Jones, JK
    Fife, D
    Goehring, E
    She, DW
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2003, 12 (04) : 295 - 301
  • [7] ADVERTISEMENTS FOR MEDICINES IN LEADING MEDICAL JOURNALS IN 18 COUNTRIES - A 12-MONTH SURVEY OF INFORMATION-CONTENT AND STANDARDS
    HERXHEIMER, A
    LUNDBORG, CS
    WESTERHOLM, B
    [J]. INTERNATIONAL JOURNAL OF HEALTH SERVICES, 1993, 23 (01): : 161 - 172
  • [8] A survey of the advertising of nine new drugs in the general practice literature
    Jones, M
    Greenfield, S
    Bradley, C
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1999, 24 (06) : 451 - 460
  • [9] LEXCHIN J, 1994, CAN MED ASSOC J, V151, P47
  • [10] 'Dear Doctor... ' - Evaluating the impact of risk communication efforts
    Seligman, PJ
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2003, 12 (04) : 291 - 293